BioSpace News Archive

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), today announced that its subsidiary company, MaryMed, LLC, has reached a definitive agreement to acquire the assets and operations of Maryland based Goose Landing Farms, Inc., for total consideration of $1.3 million.

Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the

Pulpdent Corporation, a Boston-area dental research and manufacturing company, has launched a beautiful, mobile-friendly new website for dentists, hygienists and other members of the dental industry.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The U.S. Federal Trade Commission has granted early termination of the waiting period under t

Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announces that the Company will host its earnings conference call on Friday, June 26, 2020 at 8:00 am Eastern Time (5:00 am Pacific Time/ 8:00 pm Beijing Time) to discuss the Company’s financial results of the first quarter ended March 31, 2020. To attend this earnings conference call, please

WW International, Inc. (Nasdaq: WW), a global wellness company powered by the world’s leading commercial weight management program, today announced that it will present at the following virtual investor conference.

Coherus BioSciences, Inc., announced that effective June 18, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 93,000 shares of the common stock of the Company to seven newly hired non-officer employees, with a per share exercise price of $16.98, the closing trading price on the grant date.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2020, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com . Hard copies of the report may be ordered free of charge by sending requests to: Taro Pharmaceuticals

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful completion of a $50 million Series C financing

PRECISIONscientia, a Pennsylvania-based medical communications agency specializing in interpreting and communicating the innovative science and data for cutting-edge therapies, announces it is a recipient of the Philadelphia Business Journal’s 2020 Best Places to Work Awards in the large company category.